Screener
ImmunityBio, Inc. IBRX Segment Reporting — Impairment of intangible assets
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill.
The source filing: ImmunityBio, Inc.’s 10-K, filed February 23, 2026.
- Filed
- Feb 23, 2026, 5:24 PM EST
- Fiscal year
- FY2025
- Accession
- 0001326110-26-000030
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Total internal research and development expense | 189,286 | 160,876 | 165,242 |
| Total research and development expense (including amounts with related parties) | 218,559 | 190,144 | 232,366 |
| Selling, general and administrative (including amounts with related parties) | 150,003 | 168,783 | 129,620 |
| Impairment of intangible assets | — | — | 886 |
| Total operating expenses | 368,562 | 358,927 | 362,872 |
| Loss from operations | (256,027) | (344,182) | (362,250) |
| Other income (expense), net | |||
| Interest and investment income, net | 6,405 | 7,975 | 1,131 |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is ImmunityBio, Inc.'s segment reporting — impairment of intangible assets?
- ImmunityBio, Inc. (IBRX) reported segment reporting — impairment of intangible assets of $0 in Q4 2025.
- What is the long-term trend for ImmunityBio, Inc.'s segment reporting — impairment of intangible assets?
- Over 3 years (2022 to 2025), ImmunityBio, Inc.'s segment reporting — impairment of intangible assets has grown at a -100.0% compound annual growth rate (CAGR), from $681K to $0.
- What does segment reporting — impairment of intangible assets mean?
- This metric represents the non-cash charge recognized when the carrying value of an intangible asset exceeds its fair value. It reflects a downward adjustment in the valuation of assets such as patents, licenses, or acquired intellectual property within a specific business segment. Frequent impairment charges may indicate overvaluation of acquired assets or a decline in the commercial viability of the segment's pipeline.
Ask your AI about ImmunityBio, Inc.'s segment reporting — impairment of intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude